Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Applied BioCode's Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-199.5 Mil. Therefore, Applied BioCode's EV-to-EBIT ratio for today is -9.04.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Applied BioCode's Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-143.2 Mil. Therefore, Applied BioCode's EV-to-EBITDA ratio for today is -12.60.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Applied BioCode's Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$475.2 Mil. Therefore, Applied BioCode's EV-to-Revenue ratio for today is 3.80.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Applied BioCode's Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-235.5 Mil. Therefore, Applied BioCode's EV-to-FCF ratio for today is -7.66.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Applied BioCode (TPE:6598) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-199.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-143.2 Mil.
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$475.2 Mil.
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-226.6 Mil.
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil.
Applied BioCode's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-235.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode Enterprise Value Related Terms
Applied BioCode Enterprise Value Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Applied BioCode's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Applied BioCode's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$1,803.4 Mil mean?
Applied BioCode (TPE:6598) has a Enterprise Value of NT$1,803.4 Mil as of Jul. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Applied BioCode and its competitors.
Is Applied BioCode's Enterprise Value too high?
Applied BioCode's current Enterprise Value is NT$1,803.4 Mil. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Enterprise Value compare to ABT and SYK?
Applied BioCode's Enterprise Value of NT$1,803.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Applied BioCode and its competitors. Applied BioCode's current Enterprise Value is NT$1,803.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.33, compared to a current price of NT$22.50 — trading 3.6% below its estimated fair value. The current Enterprise Value is NT$1,803.4 Mil. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Enterprise Value is NT$1,803.4 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$22.50 is trading 3.6% below its estimated GF Value™ of NT$23.33.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Enterprise Value: NT$1,803.4 Mil
GF Value™: NT$23.33 vs. price of NT$22.50 (3.6% below fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
